Human papillomavirus type 11 L1 capsid protein antigen
- Generic Name
- Human papillomavirus type 11 L1 capsid protein antigen
- Brand Names
- Gardasil, Gardasil 9
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- Z845VHQ61P
- Background
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.
The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.
- Associated Conditions
- Human Papillomavirus (HPV) Infections, Infection caused by human papillomavirus type 11
- Associated Therapies
- -
Assessing Durable Antibody Response to HPV Vaccination
- Conditions
- HPV
- Interventions
- First Posted Date
- 2021-09-01
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Emory University
- Target Recruit Count
- 44
- Registration Number
- NCT05031078
- Locations
- 🇺🇸
The Hope Clinic of Emory University, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
- Conditions
- Idiopathic CD4 T Cell Lymphocytopenia
- Interventions
- Biological: Gardasil 9
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 54
- Registration Number
- NCT03519464
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
- Conditions
- Papillomavirus VaccinesAdolescentHuman Immunodeficiency VirusHuman Papillomavirus- 6, 11, 16, 18
- Interventions
- Biological: GardasilBehavioral: Survey
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00798265
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.